Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2016-04-27 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
第二届董事会第三十五次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Shandong Ruikang Pharmaceutical Co., Ltd. It details the approval of the 2016 first quarter report and multiple credit facility applications. The document includes voting results and authorizations for management to handle credit agreements. It is not the actual quarterly report but a board meeting resolution announcement. The content focuses on board decisions and approvals, including financial credit matters, but does not contain the full financial statements or detailed financial analysis itself. The document length is 3119 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full interim report. Therefore, the best classification is Board/Management Information (MANG), as it announces board meeting resolutions and management authorizations.
2016-04-27 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" which translates to "Internal Control Assurance Report." It is issued by a certified public accounting firm and addresses the internal control effectiveness related to the financial reporting of the company for the fiscal year ending December 31, 2015. The content includes detailed descriptions of the company's internal control systems, their implementation, evaluation, and the auditor's opinion on the effectiveness of these controls. It does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a standalone audit-related report focusing on internal control over financial reporting. This matches the definition of an Audit Report / Information (AR). The document length is substantial (over 12,000 characters), indicating it is the report itself, not just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2015
2016-04-19 Chinese
2015年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the annual status of raised funds' deposit and usage for the year 2015 by 山东瑞康医药股份有限公司. It details the amounts raised through various stock issuances, the usage of these funds, bank accounts holding the funds, approvals by the board, and compliance with regulatory requirements. It includes detailed tables showing the use of funds, investment projects, and reconciliations. The document is not a full annual report or interim financial report but a focused report on the management and use of capital raised through equity issuance. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is substantial (over 13,000 characters), and it contains detailed substantive data, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2016-04-19 Chinese
2015年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2015 Annual Report Summary" of 山东瑞康医药股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2015, including revenue, net profit, quarterly data, business segments, and management discussion and analysis. It also includes information on business operations, acquisitions, and future outlook. The length of the document (over 10,000 characters) and the presence of comprehensive financial and operational data confirm it is a substantive financial report rather than a brief announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K) as it covers the company's yearly activity and full financial performance. FY 2015
2016-04-19 Chinese
关于2015年度内部控制的自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2015年度内部控制的自我评价报告" which translates to "2015 Annual Internal Control Self-Evaluation Report." It is a detailed report discussing the company's internal control system, governance, risk management, financial controls, audit functions, and compliance with regulatory requirements. The document includes a statement from the board of directors, descriptions of internal control principles, organizational structure, implementation, supervision, and identified issues with corrective plans. It is a comprehensive internal control evaluation report for the fiscal year 2015. This type of document aligns with an Audit Report / Information (AR) category, as it focuses on internal control evaluation and audit-related information rather than a full annual report or other categories. The document length (8398 characters) and content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2015
2016-04-19 Chinese
独立董事2015年度述职报告（吴国芝）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2015 Annual Work Report" for Shandong Ruikang Pharmaceutical Co., Ltd. It is a detailed report by an independent director summarizing their duties, attendance, opinions on board matters, investigations, committee roles, investor protection efforts, and training during the 2015 fiscal year. The content focuses on governance, oversight, and director responsibilities rather than financial results or audit opinions. It does not contain financial statements or audit results but rather a narrative on the director's activities and governance role. This aligns with a Board/Management Information filing, which covers announcements or reports related to board or senior management activities. The document length is 2833 characters, which is relatively short but contains substantive content about board activities rather than a mere announcement. Therefore, the best classification is MANG (Board/Management Information).
2016-04-19 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.